Results 41 to 50 of about 3,554 (229)
Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant [PDF]
, 2016 Background: Growth hormone secreting pituitary adenomas (somatotroph adenoma) predominantly express somatostatin receptors (SSTRs) subtypes 2 and 5. Higher SSTR2 expression on somatotroph adenomas results in a better response to somatostatin analogues ...
Dallenga, A.H.G. +7 more
core +1 more source
Frontiers in Endocrinology, 2020 ContextHypertension is a major cardiovascular risk factor related to increased mortality in acromegaly. Surgical cure of acromegaly is associated with improvement in blood pressure levels, however little is known about the effect of pegvisomant (PEGV ...
Greisa Vila +7 more
doaj +1 more source
A long-acting GH receptor antagonist through fusion to GH binding protein. [PDF]
, 2016 Acromegaly is a human disease of growth hormone (GH) excess with considerable morbidity and increased mortality. Somatostatin analogues are first line medical treatment but the disease remains uncontrolled in up to 40% of patients.
Artymiuk, P.J. +5 more
core +1 more source
Management of persistent acromegaly following primary therapy: The current landscape in the UK
Endocrinology, Diabetes & Metabolism, 2020 Acromegaly is the clinical consequence of chronic exposure of the tissues to excess GH and IGF‐I. It is almost exclusively the result of a GH‐secreting pituitary adenoma.
Nikolaos Kyriakakis +3 more
doaj +1 more source
Ghrelin drives GH secretion during fasting in man [PDF]
, 2002 OBJECTIVES: In humans, fasting leads to elevated serum GH concentrations. Traditionally, changes in hypothalamic GH-releasing hormone and somatostatin release are considered as the main mechanisms that induce this elevated GH ...
Bidlingmaier, M. (Martin) +8 more
core +1 more source
Predictors and rates of treatment-resistant tumor growth in acromegaly [PDF]
, 2005 Background: Multimodal therapy for acromegaly affords adequate disease control for many patients; however, there remains a subset of individuals that exhibit treatment-resistant disease.
Besser, G. M., Burman, P., Daly, Adrian
core +1 more source
Indian Journal of Endocrinology and Metabolism, 2013 Acromegaly is characterized by chronic, excess secretion of growth hormone (GH) from a pituitary adenoma, and elevated hepatic insulin-like growth factor 1 (IGF-1) levels.
Gaya Thanabalasingham, Ashley B Grossman
doaj +1 more source
Acromegaly: pathogenesis & treatment [PDF]
, 2019 Acromegaly is a multi-system disorder whose etiology is most often traced back to a growth hormone-secreting pituitary adenoma (PA). Growth hormone (GH) secretion promotes insulin-like growth factor 1 (IGF-1) release from peripheral tissues, leading to ...
Tilvawala, Megha
core
ECS-Komplex – ein neuer Biomarker bei Wachstumshormonstörungen? [PDF]
, 2016 Störungen im Metabolismus des Wachstumshormons können sich als Wachstumshormonmangel oder -überschuss (Akromegalie) äußern. In beiden Fällen handelt es sich um seltene Krankheiten, die aufwendig behandelt werden müssen, da jeder Patient anders auf seine ...
Biering, Henrik +3 more
core +1 more source
Clinical Endocrinology, Volume 103, Issue 5, Page 703-710, November 2025.ABSTRACT Objective Balance impairment is an underrecognized complication of acromegaly with potentially serious consequences for affected patients. In this study, we aimed to assess the balance in patients with long‐term acromegaly compared to non‐acromegalic controls. Design Cross‐sectional study.
Christian Rosendal +4 more
wiley +1 more source